Upadacitinib Matching Placebo
Sponsors
Abbvie Deutschland GmbH & Co. KG, AbbVie, University of North Carolina, Chapel Hill
Conditions
Axial SpondyloarthritisEoEEosinophilic EsophagitisEosinophilic Esophagitis (EoE)Rheumatoid Arthritis
Phase 2
Phase 3
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
CompletedCTIS2022-501018-78-00
Start: 2020-03-23End: 2024-04-30Target: 272Updated: 2022-12-13
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
CompletedNCT05814627
Start: 2023-06-15End: 2026-07-15Updated: 2026-08-14